QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer

QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer

Objective: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m2) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment of...

Full description

Bibliographic Details
Main Authors: Hiromi Okuyama, Seigo Nakamura, Sadako Akashi-Tanaka, Terumasa Sawada, Takashi Kuwayama, Satoko Handa, Yasuhisa Kato
Format: Article
Language:English
Published: Galenos Publishing House 2018-10-01
Series:European Journal of Breast Health
Subjects:
breast cancer therapy
side effect
quality of life
patient support system
Online Access: http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/qol-evaluation-of-nab-paclitaxel-and-docetaxel-for/42023

Internet

http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/qol-evaluation-of-nab-paclitaxel-and-docetaxel-for/42023

Similar Items